UBC research recommends graduated return to work after prostatectomy

April 02, 2019

New UBC research cautions men recovering from a radical prostatectomy to take it easy when returning to work.

School of Nursing Professors Joan Bottorff and John Oliffe are scientists with UBC's Men's Health Research program. They, along with study lead Wellam Yu Ko, recently published research exploring the journey back into the workforce following surgery to remove prostate cancer. Their research concluded a graduated or 'reduced workload' program is the best option following a radical prostatectomy.

"Most men are told by their physicians that it will take about four weeks after prostatectomy before they are back at work and at 100 per cent," says Bottorff. "But that's not the truth for most men. They do not fully anticipate the difficulties of returning to work and can't quite cope with the workload. In fact, men are often surprised at how long their full recovery can take."

The Canadian Cancer Society reports that 21,300 Canadian men were diagnosed with prostate cancer in 2017. With more than 40 per cent of all prostate cancer diagnoses happening between the ages of 60 and 69 years, a substantial proportion of new cases occur in working men under the age of 59.

A radical prostatectomy results in a long period of recovery. It is often accompanied by urinary side effects, abdominal pain and reduced mobility. As a result, men's ability to work is reduced, disrupting their sense of purpose and ability to provide for their family.

The study showed that men didn't want to appear sick or weak, but felt pressured to return to work as quickly as possible.

"It's clear they are not pitching in the same level as they did previously and they worry their workmates are going to think less of them," says Bottorff, director of the Institute for Healthy Living and Chronic Disease Prevention. "This is more the case in men who do not have a lot of control of their work schedules, or have a physically demanding job."

Yu Ko cites the experience of a self-employed businessman who returned to work full-time shortly after prostatectomy due to financial reasons. However, he was physically unable to exert himself and struggled to meet work demands. As a result, he thought of leaving his job but eventually opted to work part-time to support his family.

Other study participants noted a lack of concentration, not able to lift heavy items, and they found a full workday mentally and physically challenging. Many also reported the most common side effects of fatigue and urinary incontinence were unexpected and severely affected their return to work.

"When patients don't feel like they are performing at 100 per cent, all day long, they think about bowing out and taking retirement," Oliffe explains. "But, ending a career because of prostate cancer or after a prostatectomy isn't seen as going out on a high point and the prospect of early retirement can be quite upsetting."

The researchers say those considering a prostatectomy need to have a conversation with their employer before surgery about coming back on a graduated schedule, reducing physical labour and being prepared for a two-to six-month recovery. The study also suggests healthcare providers lobby in favour of return to work conditions that will not jeopardize a man's ongoing recovery after surgery.

"We find if they do come back to work after that conversation and they are good to go, it's still better to under promise than under deliver," says Oliffe. "Going back to work isn't always a choice and we highly recommend patients have a plan for a graduated return."

The study, published recently in Qualitative Health Research, was led by doctoral student Wellam Yu Ko with partial support by a Canadian Institutes of Health Research grant.

University of British Columbia Okanagan campus

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.